NCT05893108 is a Phase 1, PHASE2 clinical trial of Ethosomal gel bearing losartan 5% in Keloid, sponsored by Yuni Eka Anggraini.

Who is sponsoring NCT05893108?

NCT05893108 is sponsored by Yuni Eka Anggraini.

What drugs are being tested in NCT05893108?

Interventions in NCT05893108: Ethosomal gel bearing losartan 5%, triamcinolone acetonide 10 mg/ml.

Is NCT05893108 still recruiting?

NCT05893108 is currently status unknown. Last updated 5 December 2023.

Last reviewed 2023-12-05 · How we verify

NCT05893108

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ethosomal Gel Bearing Losartan 5% for Keloid Treatment

Status unknown Phase 1, PHASE2 Last updated 5 December 2023

What this trial tests

Phase 1, PHASE2 trial testing Ethosomal gel bearing losartan 5% in Keloid in 46 participants. Status unknown.

Timeline

30 March 2024

Primary endpoint
30 September 2024

30 October 2024

Quick facts

Lead sponsor	Yuni Eka Anggraini
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	46
Start date	30 March 2024
Primary completion	30 September 2024
Estimated completion	30 October 2024
Sites	1 location across Indonesia

Drugs / interventions tested

Ethosomal gel bearing losartan 5% — full drug profile →
triamcinolone acetonide 10 mg/ml — full drug profile →

Conditions studied

Keloid — all drugs for Keloid →

Sponsor

Yuni Eka Anggraini — full company profile →

Who can join

18 and older, any sex, with Keloid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objectives are to compare the efficacy of pre and post-treatment and between 5% losartan potassium loaded in ethosomal gel and 10 mg/ml triamcinolone acetonide injection based on the indicator score of The patient and observer scar assessment scale 3.0 (POSAS 3.0), degree of erythema and pigmentation, area size, thickness and density of human keloids.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

A randomised clinical trial study assessing the efficacy of 5% losartan potassium loaded in ethosomal gel to treat human keloids: a trial protocol.
Anggraini YE, Trisnowati N, Martien R, Danarti R. · · 2024 · cited 3× · PMID 38167064 · DOI 10.1186/s13063-023-07880-2
Current State of Clinical Trials for Keloid Management: An Analysis of Trials Registered on ClinicalTrials.gov.
Park S, Li D, Guo L, Xu X. · · 2026 · PMID 42077711 · DOI 10.7759/cureus.106243
Beyond blood pressure: the renin-angiotensin system as an innovative driver and therapeutic target in pathological scarring.
Shi BH, Zhang XG, Fang QQ, Xu K, et al · · 2026 · PMID 41868115 · DOI 10.3389/fphar.2026.1792119
One Molecule, Many Faces: Repositioning Cardiovascular Agents for Advanced Wound Healing
Gościniak A, Stasiłowicz-Krzemień A, Michniak-Kohn B, Fiedor P, et al · · 2024
A randomised clinical trial study assessing the efficacy of 5% losartan potassium loaded in ethosomal gel based on POSAS 3.0 score, degree of erythema and pigmentation, surface area, thickness and pliability of human keloids: a study protocol
Anggraini YE, Trisnowati N, Martien R, Danarti R. · · 2023 · DOI 10.21203/rs.3.rs-3149969/v1

Verify or expand the search:

Other recruiting trials for Keloid

Currently open trials in the same condition.

NCT06431360 — Effect of Strontium-90 Brachytherapy Combined With Hyperthermia in the Treatment of Keloid · NA · recruiting
NCT06138964 — Comparing the Effect of siSPARC Microneedle Patch Versus siSPARC+siLR4A Microneedle Patch on Post-surgical Scars · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05893108 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yuni Eka Anggraini
Last refreshed: 5 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05893108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing